DK3820569T3 - Antistofmolekyler der binder pd-l1 og cd137 - Google Patents

Antistofmolekyler der binder pd-l1 og cd137 Download PDF

Info

Publication number
DK3820569T3
DK3820569T3 DK19740347.0T DK19740347T DK3820569T3 DK 3820569 T3 DK3820569 T3 DK 3820569T3 DK 19740347 T DK19740347 T DK 19740347T DK 3820569 T3 DK3820569 T3 DK 3820569T3
Authority
DK
Denmark
Prior art keywords
binding
antibody molecules
antibody
molecules
Prior art date
Application number
DK19740347.0T
Other languages
English (en)
Inventor
Matthew Lakins
Jose Munoz-Olaya
Francisca Wollerton
Sarah Batey
Mihriban Tuna
Alexander Koers
Original Assignee
Invox Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1811405.8A external-priority patent/GB201811405D0/en
Priority claimed from GBGB1818283.2A external-priority patent/GB201818283D0/en
Priority claimed from GBGB1902594.9A external-priority patent/GB201902594D0/en
Application filed by Invox Pharma Ltd filed Critical Invox Pharma Ltd
Application granted granted Critical
Publication of DK3820569T3 publication Critical patent/DK3820569T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK19740347.0T 2018-07-12 2019-07-12 Antistofmolekyler der binder pd-l1 og cd137 DK3820569T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1811405.8A GB201811405D0 (en) 2018-07-12 2018-07-12 Antibody molecules that bind PD-L1 and CD137
GBGB1818283.2A GB201818283D0 (en) 2018-11-09 2018-11-09 Antibody molecules that bind PD-L1 and CD137
GBGB1902594.9A GB201902594D0 (en) 2019-02-26 2019-02-26 Antibody molecules that bind pd-l1 and cd137
PCT/EP2019/068793 WO2020011964A1 (en) 2018-07-12 2019-07-12 Antibody molecules that bind pd-l1 and cd137

Publications (1)

Publication Number Publication Date
DK3820569T3 true DK3820569T3 (da) 2025-01-02

Family

ID=67303457

Family Applications (1)

Application Number Title Priority Date Filing Date
DK19740347.0T DK3820569T3 (da) 2018-07-12 2019-07-12 Antistofmolekyler der binder pd-l1 og cd137

Country Status (18)

Country Link
US (2) US12344672B2 (da)
EP (2) EP4512417A3 (da)
JP (2) JP7360440B2 (da)
KR (1) KR102926972B1 (da)
CN (1) CN112423845B (da)
AU (1) AU2019301204B2 (da)
BR (1) BR112021000394A2 (da)
CA (1) CA3106046A1 (da)
DK (1) DK3820569T3 (da)
ES (1) ES3006183T3 (da)
IL (1) IL280004A (da)
MX (1) MX2021000398A (da)
PL (1) PL3820569T3 (da)
PT (1) PT3820569T (da)
SG (1) SG11202100170RA (da)
TW (1) TWI861005B (da)
WO (1) WO2020011964A1 (da)
ZA (1) ZA202100717B (da)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018076525A2 (pt) 2016-06-20 2019-04-02 F-Star Beta Limited membros de ligação a lag-3
GB201612520D0 (en) 2016-07-19 2016-08-31 F-Star Beta Ltd Binding molecules
IL272159B2 (en) 2017-08-04 2026-03-01 Genmab As PD-L1 and CD137 binding agents and their use
JP7489316B2 (ja) 2017-12-19 2024-05-23 エフ－スター セラピューティクス リミテッド Ｐｄ－ｌｉ抗原結合部位を有するｆｃ結合断片
CN112585165B8 (zh) 2018-04-25 2025-02-14 普罗米修斯生物科学公司 优化的抗tl1a抗体
GB201811403D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Antibody molecules
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
AU2019301206B2 (en) 2018-07-12 2025-10-30 Invox Pharma Limited Antibody molecules that bind CD137 and OX40
GB201811408D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd CD137 Binding Molecules
GB201811404D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-CD137 Antibodies
GB201811450D0 (en) 2018-07-12 2018-08-29 F Star Delta Ltd Mesothelin and CD137 binding molecules
GB201811415D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-Mesothelin Anti bodies
IL317002A (en) 2018-08-10 2025-01-01 Chugai Pharmaceutical Co Ltd Anti-CD137 antigen binding molecule and use thereof
CN114901311A (zh) 2019-10-24 2022-08-12 普罗米修斯生物科学公司 Tnf样配体1a（tl1a）的人源化抗体及其用途
US20230087164A1 (en) * 2020-02-04 2023-03-23 Genmab A/S Antibodies for use in therapy
TWI895351B (zh) * 2020-02-12 2025-09-01 日商中外製藥股份有限公司 用於癌症之治療的抗cd137抗原結合分子
EP4134377A4 (en) * 2020-05-06 2024-05-15 Korea University Research and Business Foundation PD-1 VARIANTS WITH INCREASED PD-L1 AFFINITY
AU2021271695A1 (en) * 2020-05-14 2022-08-18 Elixiron Immunotherapeutics (hong Kong) Limited Anti-PD-L1 antibodies and anti-PD-L1/IL10 fusion proteins
MX2023008172A (es) * 2021-01-08 2023-07-18 Beijing Hanmi Pharmaceutical Co Ltd Anticuerpo biespecifico de forma heterodimerica similar a la estructura del anticuerpo natural anti-pd-l1/anti-4-1bb y preparacion del mismo.
EP4395824A4 (en) * 2021-09-03 2025-10-22 Novarock Biotherapeutics Ltd BISPECIFIC AND TRISPECIFIC PD-L1, CD137 AND/OR TGF-BETA BINDING PROTEINS AND USES THEREOF
CN114702569B (zh) * 2022-05-25 2023-01-10 深圳吉诺因生物科技有限公司 Pd-l1相关疫苗及其应用
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
AU2024279278A1 (en) 2023-05-31 2025-12-18 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
TW202519547A (zh) * 2023-07-10 2025-05-16 美商再生元醫藥公司 雙特異性PD-L1x4-1BB抗體及其使用方法
IL327045A (en) 2023-10-05 2026-05-01 Capstan Therapeutics Inc Structure-restricted ionizable cationic lipids and lipid nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025242842A1 (en) 2024-05-22 2025-11-27 Invox Pharma Limited Dosage regimes for the administration of an anti-cd137/pd-l1 antigen-binding protein
WO2025242843A1 (en) 2024-05-22 2025-11-27 Invox Pharma Limited Dosage regimes for the administration of an anti-cd137/pd-l1 antigen-binding protein

Family Cites Families (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2245404C3 (de) 1972-09-15 1978-08-31 Robert Bosch Gmbh, 7000 Stuttgart Massewiderstand, insbesondere für Zündkerzen, sowie Verfahren zur Herstellung desselben
JPS531908B2 (da) 1973-11-12 1978-01-23
JPS5746634B2 (da) 1974-05-10 1982-10-04
JPS5146628A (ja) 1974-10-17 1976-04-21 Nippon Denso Co Teikoirisupaakupuragu
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
AU695584B2 (en) 1993-01-28 1998-08-20 Novartis Pharmaceutical Corporation Human monoclonal antibodies to cytomegalovirus
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
ES2255194T3 (es) 1997-12-01 2006-06-16 The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services Anticuerpos, que incluyen moleculas fv, e inmunoconjugados que presentan una afinidad de enlace elevada para la mesotelina y metodos para su utilizacion.
DE19818214A1 (de) 1998-04-24 1999-10-28 Bosch Gmbh Robert Zündkerze für eine Brennkraftmaschine
DE60039510D1 (de) 1999-05-27 2008-08-28 Us Gov Health & Human Serv Immunokonjugate mit hoher bindungsaffinität
AU2001247616B2 (en) 2000-04-11 2007-06-14 Genentech, Inc. Multivalent antibodies and uses therefor
JP4578025B2 (ja) 2001-07-06 2010-11-10 日本特殊陶業株式会社 スパークプラグ
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
US20090298195A1 (en) 2005-01-05 2009-12-03 F-Star Biotechnologische Forschungs-Und Entwicklun Gseges M.B.H. Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
EP2399935A3 (en) 2005-02-15 2012-02-22 GTC Biotherapeutics, Inc. An anti-CD137 antibody as an agent in the treatment of cancer and glycosylation variants thereof
EP2322560B1 (en) 2005-03-10 2013-09-04 Morphotek, Inc. Anti-mesothelin antibodies
CA2612241C (en) 2005-07-01 2018-11-06 Medarex, Inc. Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
AT503889B1 (de) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F Multivalente immunglobuline
GB0624500D0 (en) 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
PL3241842T3 (pl) 2007-06-26 2024-06-10 F-Star Therapeutics Limited Prezentacja środków wiążących
HUE027358T2 (en) 2007-11-26 2016-09-28 Bayer Ip Gmbh Anti-mesothelin antibodies and their applications
KR101577843B1 (ko) 2007-12-14 2015-12-16 브리스톨-마이어스 스큅 컴퍼니 인간 ｏｘ４０ 수용체에 대한 결합 분자
PT2132228E (pt) 2008-04-11 2011-10-11 Emergent Product Dev Seattle Imunoterapia de cd37 e sua combinação com um quimioterápico bifuncional
EP2113255A1 (en) 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Cytotoxic immunoglobulin
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
WO2010057047A1 (en) 2008-11-13 2010-05-20 Trubion Pharmaceutics, Inc. Cd37 immunotherapeutic combination therapies and uses thereof
EP4209510B1 (en) 2008-12-09 2024-01-31 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
AU2010230063B2 (en) 2009-03-24 2015-06-25 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Anti-mesothelin antibodies
UY32560A (es) 2009-04-29 2010-11-30 Bayer Schering Pharma Ag Inmunoconjugados de antimesotelina y usos de los mismos
NO2504364T3 (da) 2009-11-24 2018-01-06
EP2407487A1 (en) 2010-07-14 2012-01-18 F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. Multispecific modular antibody
SG10201912092VA (en) 2010-09-09 2020-02-27 Pfizer 4-1bb binding molecules
PE20170917A1 (es) 2010-12-20 2017-07-12 Genentech Inc Anticuerpos anti-mesotelina e inmunoconjugados
ES2692268T5 (en) 2011-03-29 2025-02-26 Roche Glycart Ag Antibody fc variants
EP2546268A1 (en) 2011-07-13 2013-01-16 F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. Internalising immunoglobulin
US9624298B2 (en) 2011-11-28 2017-04-18 Merck Patent Gmbh Anti-PD-L1 antibodies and uses thereof
AU2013267161A1 (en) 2012-05-31 2014-11-20 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-L1
WO2014004549A2 (en) 2012-06-27 2014-01-03 Amgen Inc. Anti-mesothelin binding proteins
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
JP5276742B1 (ja) 2012-08-09 2013-08-28 日本特殊陶業株式会社 点火プラグ
WO2014052064A1 (en) 2012-09-27 2014-04-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mesothelin antibodies and methods for eliciting potent antitumor activity
EP2925350B1 (en) 2012-12-03 2019-01-30 Bristol-Myers Squibb Company Enhancing anti-cancer activity of immunomodulatory fc fusion proteins
US10280221B2 (en) 2013-03-15 2019-05-07 Glaxosmithkline Intellectual Property Development Limited Anti-LAG-3 binding proteins
MX357011B (es) 2013-03-15 2018-06-22 Amgen Inc Anticuerpos biespecificos heterodimericos.
EP3757130A1 (en) 2013-09-26 2020-12-30 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
GB201317622D0 (en) 2013-10-04 2013-11-20 Star Biotechnology Ltd F Cancer biomarkers and uses thereof
ES2783026T3 (es) 2014-02-04 2020-09-16 Pfizer Combinación de un antagonista de PD-1 y un agonista de 4-1BB para el tratamiento de cáncer
WO2015138920A1 (en) 2014-03-14 2015-09-17 Novartis Ag Antibody molecules to lag-3 and uses thereof
US20150307620A1 (en) 2014-04-16 2015-10-29 University Of Connecticut Linked immunotherapeutic agonists that costimulate multiple pathways
JP5902757B2 (ja) 2014-06-24 2016-04-13 日本特殊陶業株式会社 スパークプラグ
WO2015198312A1 (en) 2014-06-24 2015-12-30 Ccam Therapeutics Ltd. Compositions comprising antibodies to ceacam-1 and lag-3 for cancer therapy
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
BR112017002596A2 (pt) 2014-08-10 2018-01-30 Federal-Mogul Ignition Company vela de ignição com vedação melhorada
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
WO2016040882A1 (en) 2014-09-13 2016-03-17 Novartis Ag Combination therapies of egfr inhibitors
TW201619200A (zh) 2014-10-10 2016-06-01 麥迪紐有限責任公司 人類化抗－ｏｘ４０抗體及其用途
CA2874083C (en) 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
LT3623386T (lt) 2015-01-08 2022-08-10 BioNTech SE Agonistiniai tnf receptorius surišantys agentai
GB201500319D0 (en) 2015-01-09 2015-02-25 Agency Science Tech & Res Anti-PD-L1 antibodies
AU2016219772A1 (en) 2015-02-22 2017-09-21 Sorrento Therapeutics, Inc. Antibody therapeutics that bind CD137
WO2016162505A1 (en) 2015-04-08 2016-10-13 F-Star Biotechnology Limited Her2 binding agent therapies
AU2016258977C1 (en) 2015-05-04 2022-07-14 Pieris Pharmaceuticals Gmbh Anti-cancer fusion polypeptide
AU2016265447B2 (en) 2015-05-21 2022-06-16 Alligator Bioscience Ab Novel polypeptides
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
JP6025921B1 (ja) 2015-06-22 2016-11-16 日本特殊陶業株式会社 スパークプラグ
CA2988831A1 (en) 2015-07-15 2017-01-19 Pieris Pharmaceuticals Gmbh Novel proteins specific for lag-3
CN114853891A (zh) 2015-07-22 2022-08-05 索伦托药业有限公司 与lag3结合的抗体治疗剂
AU2016298227B9 (en) * 2015-07-30 2019-10-31 Macrogenics, Inc. PD-1-binding molecules and methods of use thereof
EP3331901A1 (en) 2015-08-07 2018-06-13 Pieris Pharmaceuticals GmbH Novel fusion polypeptide specific for lag-3 and pd-1
CN113214398B (zh) 2015-09-22 2022-04-08 苏州丁孚靶点生物技术有限公司 抗人cd137的完全人抗体及其应用
KR101782487B1 (ko) 2015-09-24 2017-09-27 재단법인 목암생명과학연구소 신규 항-메소텔린 항체 및 이를 포함하는 조성물
BR112018002570A2 (pt) 2015-10-02 2018-10-16 Hoffmann La Roche molécula de ligação ao antígeno biespecífica, anticorpo biespecífico, polinucleotídeos, anticorpo que se liga especificamente ao ox40, composição farmacêutica e método para inibir o crescimento de células tumorais em um indivíduo
TWI756187B (zh) 2015-10-09 2022-03-01 美商再生元醫藥公司 抗ｌａｇ３抗體及其用途
GB201519481D0 (en) 2015-11-04 2015-12-16 Cancer Rec Tech Ltd Immunomodulatory antibodies
CA3132021C (en) 2015-11-18 2024-03-12 Merck Sharp & Dohme Corp. Pd1 and/or lag3 binders
US20190330336A1 (en) 2015-11-19 2019-10-31 Sutro Biopharma, Inc. Anti-lag3 antibodies, compositions comprising anti-lag3 antibodies and methods of making and using anti-lag3 antibodies
MX2018008308A (es) 2016-01-11 2019-05-15 Inhibrx Inc Proteinas de fusion de union a 41bb multivalentes y multiespecificas.
CN108602371B (zh) 2016-03-18 2020-03-24 大日本印刷株式会社 中间转印介质、中间转印介质与热转印片的组合、以及印刷物的形成方法
WO2017182672A1 (en) 2016-04-22 2017-10-26 Alligator Bioscience Ab Novel bispecific polypeptides against cd137
AR108377A1 (es) 2016-05-06 2018-08-15 Medimmune Llc Proteínas de unión biespecíficas y sus usos
KR20190014525A (ko) 2016-05-27 2019-02-12 애브비 바이오테라퓨틱스 인크. 면역 조절 단백질과 종양 항원을 결합하는 이중특이적 결합 단백질
US20190106494A1 (en) 2016-06-13 2019-04-11 Askgene Pharma Inc. PD-L1 Specific Monoclonal Antibodies for Disease Treatment and Diagnosis
EP3858858A1 (en) 2016-06-20 2021-08-04 F-Star Delta Limited Binding molecules binding pd-l1 and lag-3
JP7461741B2 (ja) 2016-06-20 2024-04-04 カイマブ・リミテッド 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
BR112018076525A2 (pt) 2016-06-20 2019-04-02 F-Star Beta Limited membros de ligação a lag-3
CN107523546A (zh) 2016-06-20 2017-12-29 上海细胞治疗研究院 一种高效稳定表达抗体的nk细胞及其用途
GB201612520D0 (en) 2016-07-19 2016-08-31 F-Star Beta Ltd Binding molecules
KR20190031299A (ko) 2016-07-20 2019-03-25 주식회사 에스티큐브 글리코실화된 pd-l1에 결합하는 항체의 조합을 사용하는 암 치료 방법
CN109983033B (zh) 2016-09-23 2023-10-31 美勒斯公司 调节细胞表达的生物活性的结合分子
GB201616699D0 (en) 2016-09-30 2016-11-16 Mab Designs Ltd Antibodies
GB201619648D0 (en) 2016-11-21 2017-01-04 Alligator Bioscience Ab Novel antibodies and uses thereof
WO2018115859A1 (en) 2016-12-20 2018-06-28 Kymab Limited Multispecific antibody with combination therapy for immuno-oncology
GB201700345D0 (en) 2017-01-09 2017-02-22 F-Star Beta Ltd Conditional agonists of immune responses
CA3065008A1 (en) 2017-05-26 2018-11-29 Novimmune Sa Anti-cd47 x anti-mesothelin antibodies and methods of use thereof
MX2019012038A (es) 2017-05-30 2019-11-18 Bristol Myers Squibb Co Composiciones que comprenden una combinacion de un anticuerpo anti gen 3 de activacion del linfocito (lag-3), un inhibidor de la trayectoria del receptor de muerte programada 1 (pd-1), y un agente inmunoterapeutico.
IL272159B2 (en) 2017-08-04 2026-03-01 Genmab As PD-L1 and CD137 binding agents and their use
EP3470426A1 (en) 2017-10-10 2019-04-17 Numab Therapeutics AG Multispecific antibody
EP3728314A1 (en) 2017-12-19 2020-10-28 Kymab Limited Bispecific antibody for icos and pd-l1
JP7489316B2 (ja) 2017-12-19 2024-05-23 エフ－スター セラピューティクス リミテッド Ｐｄ－ｌｉ抗原結合部位を有するｆｃ結合断片
GB201811415D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-Mesothelin Anti bodies
GB201811403D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Antibody molecules
GB201811404D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-CD137 Antibodies
GB201811450D0 (en) 2018-07-12 2018-08-29 F Star Delta Ltd Mesothelin and CD137 binding molecules
GB201811408D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd CD137 Binding Molecules
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
AU2019301206B2 (en) 2018-07-12 2025-10-30 Invox Pharma Limited Antibody molecules that bind CD137 and OX40
CA3139003A1 (en) 2019-05-14 2020-11-19 F-Star Therapeutics Limited Dosage regimes for the administration of a lag-3/pd-l1 bispecific antibody

Also Published As

Publication number Publication date
MX2021000398A (es) 2021-05-27
AU2019301204A1 (en) 2021-02-25
EP3820569B1 (en) 2024-11-20
TW202005984A (zh) 2020-02-01
CA3106046A1 (en) 2020-01-16
WO2020011964A1 (en) 2020-01-16
EP4512417A2 (en) 2025-02-26
EP3820569A1 (en) 2021-05-19
KR20210030956A (ko) 2021-03-18
SG11202100170RA (en) 2021-02-25
US20250346679A1 (en) 2025-11-13
US12344672B2 (en) 2025-07-01
BR112021000394A2 (pt) 2021-04-06
KR102926972B1 (ko) 2026-02-20
JP2021524268A (ja) 2021-09-13
CN112423845B (zh) 2024-07-30
JP7360440B2 (ja) 2023-10-12
EP4512417A3 (en) 2025-09-17
ZA202100717B (en) 2025-09-25
ES3006183T3 (en) 2025-03-17
AU2019301204B2 (en) 2025-10-23
CN112423845A (zh) 2021-02-26
PT3820569T (pt) 2025-01-14
JP7587656B2 (ja) 2024-11-20
PL3820569T3 (pl) 2025-07-14
IL280004A (en) 2021-03-01
JP2023181176A (ja) 2023-12-21
US20220049007A1 (en) 2022-02-17
TWI861005B (zh) 2024-11-11

Similar Documents

Publication Publication Date Title
IL280004A (en) Antibody molecules that bind pd-l1 and cd137
DK3472207T3 (da) Bindingsmolekyler, der binder pd-l1 og lag-3
IL280002A (en) Antibody molecules that bind CD137 and OX40
DK3328888T5 (da) ANTI-PSMA-antistoffer, bispecifikke antigenbindingsmolekyler, der binder PSMA AND og CD3, samt anvendelser deraf
IL277848A (en) HER2-targeting antigen-binding molecules containing 4-1BBL
DK3328892T3 (da) Bispecifikke antistofkonstruktioner, der binder egfrviii og cd3
DK3487882T3 (da) Anti-gprc5d-antistoffer, bispecifikke antigenbindende molekyler, der binder gprc5d og cd3, samt anvendelser deraf
DK3370768T3 (da) Antistoffer som specifikt binder pd-1 og anvendelser deraf
DK3710484T3 (da) Ctla-4-bindende antistoffer og anvendelser deraf
IL281787A (en) Antigen-binding molecules capable of binding cd3 and cd137 but not simultaneously
DK3665198T3 (da) Antistoffer, der binder egfr og cmet
DK3582806T5 (da) Proteiner, der binder her2, nkg2d og cd16
DK3328889T3 (da) Bispecifikke antistofkonstruktioner, der binder dll3 og cd3
DK3833386T3 (da) Multispecifikke bindende proteiner, der binder her2, nkg2d og cd16, og anvendelsesmetoder
DK3223845T3 (da) Heterodimere antistoffer, der binder cd3 og cd20
DK3606955T3 (da) Bispecifikke antistoffer, der specifikt binder sig til PD1 og LAG3
DK3558369T3 (da) Antistoffer, der specifikt binder til humant il-15, og anvendelse heraf
DK3097122T3 (da) Antistoffer, der binder beta-klotho-domæne 2, og fremgangsmåder til anvendelse deraf
DK3476399T3 (da) Lag-3-antistof, antigenbindende fragment deraf og farmaceutisk anvendelse deraf
DK3328893T3 (da) Bispecifikke antistofkonstruktioner, der binder mesothelin og cd3
DK3452089T3 (da) Bispecifikke bindingsproteiner og anvendelser deraf
DK3337824T3 (da) Anti-bcma-antistoffer, bispecifikke antigen-bindende molekyler, som binder bcma og cd3, og anvendelse deraf
DK3592384T3 (da) Antistoffer, der specifikt binder til human il-1r7
DK3331912T3 (da) Indsættelige variable fragmenter af antistoffer og modificerede a1-a2-domæner af nkg2d-ligander og ikke-naturlige nkg2d-ligander, der binder ikke-naturlige nkg2d-receptorer
DK3998285T3 (da) Bindingsmolekyler til cd38 og pd-l1